Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers.

ABSTRACT:

Background

An early first full-time pregnancy substantially reduces the risk of developing breast cancer later in life. Extensive studies indicate that this protective effect is mediated by the pregnancy hormone human chorionic gonadotrophin (hCG).

Methods

In this proof-of-concept study 33 women with a BRCA mutation received recombinant-hCG (r-hCG). A 4-mm breast biopsy was obtained before (T1) and after 12 weeks of r-hCG injections (T2), as well as 6 months later (T3). The tissue was examined using RNA-sequencing methodology to determine if the 'high-risk' transcriptomic signature was converted to a 'low-risk' signature as in an early first full-time pregnancy. A stringent clinical safety monitoring was performed.

Results

The r-hCG administration was well tolerated i

SUBMITTER: Depypere H 

PROVIDER: S-EPMC8011504 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature